Drug Profile
AD 05
Alternative Names: Ab-AD05; AD-05; Affitope-AD05Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Alzheimer vaccines; Antidementias
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Alzheimer's disease in Austria (Parenteral)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Austria (Parenteral)
- 08 Sep 2016 Preclinical trials in Alzheimer's disease in Austria (Parenteral) before September 2016 (AFFiRis pipeline, September 2016)